Your session is about to expire
← Back to Search
mRNA-1653 for Human Metapneumovirus and Human Parainfluenza Infection
Study Summary
This trial will study whether a new vaccine is safe and effective in adults and children.
- Human Metapneumovirus and Human Parainfluenza Infection
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
How many venues are conducting this research endeavor?
"Currently, this medical study is running at 20 different sites across the nation. These locations span from Birmingham to Metairie and Norfolk to other cities. To reduce travel burden, it may be beneficial for participants to select a trial location near their residence."
Are there still vacancies for participants in this research endeavor?
"Contrary to expectations, the research posted on clinicaltrials.gov is no longer recruiting participants. Originally published in November 2019 and last updated in September 2022, this trial has reached its enrollment goals; however, there are 771 other active studies that may still be of interest."
Does this clinical trial provide an opportunity for individuals aged 45 and above to contribute?
"Patients aged between 12 months and 49 years old are eligible for this trial. Notably, there 200 studies open to those under 18, while 607 trials are recruiting patients above the age of 65."
To what extent can potential candidates access this medical trial?
"This trial is seeking 51 participants, aged between 12 months and 49 years old, with parainfluenza. In addition to meeting the age criterion, female enrollees must have a negative pregnancy test at Screening and on the day of vaccination; they are also required to practice adequate contraception or abstain from all activities that could lead to conception for 28 days before being vaccinated as well as 3 months following their last immunization. Furthermore, these patients must have an acceptable current body measurements (height/weight above third percentile) in accordance with Body Mass Indexes ranging from 18 kg/m^2 up to 35 kg/m^2,"
Has the Food and Drug Administration issued a stamp of approval for mRNA-1653?
"As this is an early-stage Phase 1 trial, with limited existing research to verify safety and efficacy, the evaluation team at Power gave mRNA-1653 a score of 1."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger